Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap6.87B
Enterprise Value7.63B
P/E Ratio70.56
PEG Ratio-1.41
Price/Sales Ratio2.34
Price/Book Ratio1.21
Enterprise/Revenue2.61
Enterprise/EBITDA16.48

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin0.04
Operating Margin0.09
AD

Management Effectiveness

Return On Assets0.01
Return On Equity0.02

Income Statement

Revenue5.48B
Revenue/Share3.57
Gross Profit1.74B
EBITDA846.59M
Net Income349.49M
Diluted EPS0.24

Balance Sheet

Total Cash3.55B
Total Cash/Share2.42
Total Debt2.89B
Total Debt/Equity0.25
Current Ratio2.31
Book Value Per Share8.19

Price History

52-Week Change-31.21
52-Week High5.77
52-Week Low3.74
Moving Average 50 Days4.23
Moving Average 200 Days4.69

Statistics

Average Volume565,406
Shares Outstanding3.38B
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0.14
Trailing Annual Dividend Yield1.47
Payout Ratio1.22
Last Split FactorN/A
Last Split DateN/A
AD